文献速递眼底病与葡萄膜炎

雷珠单抗港式给药系统对比监测治疗无黄斑水肿的非增殖性糖尿病视网膜病变:Pavilion随机临床试验

Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

在50个美国研究点开展的随机临床试验纳入174例中度严重至严重非增殖性糖尿病视网膜病变(NPDR)无中心受累糖尿病黄斑水肿(CI-DME)患者,按5:3随机分组至雷珠单抗港式给药系统每36周换药(PDS Q36W)组或对照组,两组每4周监测。52周时PDS Q36W组80.1%对比对照组9.0%达到DRSS至少2级改善(差异71.1%,95%CI 61.0%至81.2%,P<.001)。

要点

  • 52周时PDS Q36W组80.1%对比对照组9.0%达到DRSS至少2级改善,差异71.1%(95%CI 61.0%至81.2%,P<.001)。
  • 52周内CI-DME、PDR或ASNV发生率PDS Q36W组7.1%对比对照组47.0%,风险比0.12(95%CI 0.05至0.28,P<.001)。
  • PDS Q36W组植入后4周出现7.4字母(95%CI -10.3至-4.5)的暂时性BCVA下降,8周后恢复。

核心结论

  • 1年时PDS Q36W组达到DRSS至少2级改善的参与者 substantially 多于对照组,且发生CI-DME、PDR或ASNV的风险降低,安全性结局与既往报告一致。
  • 作者认为这些发现应与植入后4至12周的暂时性术后BCVA下降以及需要更长期BCVA和安全性结局相权衡。

研究设计与样本

  • 随机临床试验,在美国50个研究点开展,纳入18岁及以上、继发于1型或2型糖尿病的中度严重或严重NPDR(DRSS水平47或53)参与者。
  • 参与者按5:3非盲随机分组至PDS Q36W组(n=106)或对照组(n=68),两组每4周监测,共174例;平均(SD)年龄53.9(11.7)岁,女性74例(42.5%)。
  • 两组在发生CI-DME、PDR或前节新生血管(ASNV)时可接受玻璃体腔注射雷珠单抗。

主要发现

  • 第52周时,PDS Q36W组80.1%对比对照组9.0%达到ETDRS DRSS较基线至少2级改善(差异71.1%,95%CI 61.0%至81.2%,P<.001)。
  • 第52周内CI-DME、PDR或ASNV发生率PDS Q36W组7.1%对比对照组47.0%(风险比0.12,95%CI 0.05至0.28,P<.001)。
  • BCVA自基线至第52周变化:PDS Q36W组+1.4字母(95%CI -0.5至3.3字母)对比对照组-2.6字母(95%CI -5.0至-0.1字母),差异4.0字母(95%CI 0.9至7.1字母,P=.01)。
  • PDS Q36W组植入后4周出现7.4字母(95%CI -10.3至-4.5字母)的暂时性BCVA下降,8周后恢复。
  • PDS Q36W组105例中17例(16.2%)发生特别关注的眼部不良事件:白内障7例(6.7%)、玻璃体出血6例(5.7%)、结膜滤泡/结膜回缩/前房积血各2例(1.9%)、结膜糜烂和视网膜脱离各1例(1.0%),至第52周无眼内炎报告。

关键数值与推荐

  • 主要结局为第52周ETDRS DRSS较基线至少2级改善的参与者比例。
  • DRSS纳入水平为47或53(中度严重或严重NPDR)。
  • PDS Q36W组雷珠单抗浓度为100 mg/mL,每36周进行换药操作。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出这些发现应与植入后4至12周的暂时性术后BCVA下降相权衡。
  • 作者指出需要更长期的BCVA和安全性结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Frequent prophylactic intravitreal anti-vascular endothelial growth factor injections can reduce risk of progression to vision-threatening complications in nonproliferative diabetic retinopathy (NPDR). A refillable drug delivery system for continuous intraocular ranibizumab release could offer less frequent treatment regimens. OBJECTIVE: To evaluate the Port Delivery System (PDS) with ranibizumab, 100 mg/mL, with refill-exchange procedures every 36 weeks (PDS Q36W), vs no PDS (control) in moderately severe to severe NPDR without center-involved diabetic macular edema (CI-DME), monitoring both groups every 4 weeks. DESIGN, SETTING, AND PARTICIPANTS: This was a randomized clinical trial at 50 US investigational sites. Participants aged 18 years or older with moderately severe or severe NPDR (Diabetic Retinopathy Severity Scale [DRSS] level 47 or 53) secondary to type 1 or 2 diabetes were eligible. Data analysis was performed from August 10, 2020, to October 3, 2022. INTERVENTION: Participants were randomized (unmasked) 5:3 to PDS Q36W vs control. Both groups could receive intravitreal ranibizumab injections if CI-DME, proliferative diabetic retinopathy (PDR), or anterior segment neovascularization (ASNV) developed. MAIN OUTCOMES AND MEASURES: Proportion of participants with an improvement of at least 2 levels in Early Treatment Diabetic Retinopathy Study DRSS from baseline at week 52. RESULTS: A total of 174 participants (mean [SD] age, 53.9 [11.7] years; 74 [42.5%] female) were randomized to PDS Q36W (n = 106) or control (n = 68). At week 52, 80.1% of those receiving PDS Q36W vs 9.0% of control participants had at least a 2-step DRSS improvement from baseline (difference, 71.1% [95% CI, 61.0% to 81.2%]; P < .001). Secondary outcomes included rate of development of CI-DME, PDR, or ASNV through week 52 (PDS Q36W, 7.1%; control, 47.0%; hazard ratio, 0.12 [95% CI, 0.05 to 0.28]; P < .001) and best-corrected visual acuity (BCVA) change from baseline to week 52 (+1.4 letters [95% CI, -0.5 to 3.3 letters] for those receiving PDS Q36W vs -2.6 letters [95% CI, -5.0 to -0.1 letters] for control participants; difference, 4.0 letters [95% CI, 0.9 to 7.1 letters]; P = .01). The PDS Q36W group had a transient BCVA decrease of 7.4 letters (95% CI, -10.3 to -4.5 letters) at 4 weeks after implantation, resolving 8 weeks later. Ocular adverse events of special interest occurred in 17 of 105 participants (16.2%) receiving PDS Q36W (cataract, 7 participants [6.7%]; vitreous hemorrhage, 6 participants [5.7%]; conjunctival bleb, conjunctival retraction, and hyphema, each 2 participants [1.9%]; conjunctival erosion and retinal detachment, each 1 participant [1.0%]), with no endophthalmitis reported through week 52. CONCLUSIONS AND RELEVANCE: At 1 year, PDS Q36W resulted in substantially more participants achieving at least a 2-step DRSS improvement and a reduced risk of developing CI-DME, PDR, or ASNV compared with control participants, with safety outcomes consistent with previous reports. These findings should be balanced with the transient, postoperative decrease in BCVA 4 through 12 weeks after implantation and the need for longer-term BCVA and safety outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04503551.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Pieramici DJ, Awh CC, Chang M, et al. Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema: The Pavilion Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 40048178. doi:10.1001/jamaophthalmol.2025.0001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。